Navigation Links
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Date:7/15/2009

prietary MORPHODOMA((R)) technology, to improve the activity of the antibodies or develop new antibodies for potential therapeutic applications.

About Cancer Innovations, Inc.

Cancer Innovations, Inc. is a developmental stage biotechnology company dedicated to the discovery, development and commercialization of novel biopharmaceutical therapeutics, diagnostics as well as novel small molecule compound(s) with significant activity minimizing solid tumors for cancer and angiogenic diseases. The company is centered on a highly innovative and novel set of core technologies developed by its scientific founders. This exciting technology is based on proprietary discoveries concerning the importance of stromal factors uniquely present within the surrounding microenvironment of malignant tumors.

About Morphotek

Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Re
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... a carbon lattice with a honeycomb structure, has great ... electronic devices. But applications have been stymied because the ... not function effectively as a semiconductor to amplify or ... sheets into nanoscale ribbons can open up a larger ...
... , ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:New graphene 'nanomesh' could change the future of electronics 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 2Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 3Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 4Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 5Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 6
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... cancer screening tests are proven to reduce colorectal cancer mortality, ... older receive the recommended tests, according to a report in ... Prevention , a journal of the American Association for Cancer ... conducted a National Health Interview Survey and found only 50 ...
... Using an engineered common cold virus, UCLA researchers delivered ... them, using Positron Emission Tomography (PET), to locate the ... the first place prostate cancer goes before invading other ... lymph nodes are very difficult to find using conventional ...
... probably one of the most commonly used diagnostics in ... the throat while the patient says, "Aaaah". But, research ... Journal of Medical Engineering and Informatics looks set ... The technique could circumvent the problem of the failing ...
Cached Biology News:Colorectal cancer screening rates still too low 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 3Sounding out heart problems automatically 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
recombination at attR1 and attR2 sites...
...
Biology Products: